Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine

Abstract A vaccine based on native outer membrane vesicles (NOMV) that has potential to provide safe, broad based protection against group B strains of Neisseria meningitidis has been developed. Three antigenically diverse group B strains of N. meningitidis were chosen and genetically modified to im...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2010-07, Vol.28 (31), p.5057-5067
Main Authors: Zollinger, Wendell D, Donets, Mikhail A, Schmiel, Deborah H, Pinto, Valerian B, Labrie, Joseph E, Moran, Elizabeth E, Brandt, Brenda L, Ionin, Boris, Marques, Ryan, Wu, Max, Chen, Ping, Stoddard, Mark B, Keiser, Paul B
Format: Article
Language:English
Subjects:
Allergy and Immunology
Animals
Antibodies, Bacterial - blood
Antibody Formation
Antibody response
Antigens, Bacterial - immunology
Applied microbiology
Bacterial Outer Membrane Proteins - immunology
Bacteriology
Biological and medical sciences
Fundamental and applied biological sciences. Psychology
Gene Knockout Techniques
Immunogenicity
Meningococcal Vaccines - immunology
Mice
Microbiology
Miscellaneous
Molecular weight
Neisseria meningitidis
Neisseria meningitidis, Serogroup B - genetics
Neisseria meningitidis, Serogroup B - immunology
Proteins
Vaccine
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Vesicles
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract A vaccine based on native outer membrane vesicles (NOMV) that has potential to provide safe, broad based protection against group B strains of Neisseria meningitidis has been developed. Three antigenically diverse group B strains of N. meningitidis were chosen and genetically modified to improve safety and expression of desirable antigens. Safety was enhanced by disabling three genes: synX , lpxL1 , and lgtA . The vaccine strains were genetically configured to have three sets of antigens each with potential to induce protective antibodies against a wide range of group B strains. Preliminary immunogenicity studies with combined NOMV from the three strains confirmed the capacity of the vaccine to induce a broad based bactericidal antibody response. Analysis of the bactericidal activity indicated that antibodies to the LOS were responsible for a major portion of the bactericidal activity and that these antibodies may enhance the bactericidal activity of anti-protein antibodies.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2010.05.006